

## Special Issue

# Vaccine Efficacy and Safety in Patients with Immune-Mediated Intestinal Diseases

### Message from the Guest Editors

Vaccination plays a crucial role in preventing infectious diseases and promoting public health. However, individuals with immune-mediated intestinal diseases, such as inflammatory bowel disease, celiac disease, and other related conditions, present unique challenges and considerations regarding vaccine efficacy and safety. Understanding the specific challenges and considerations is essential for optimizing vaccination strategies in this vulnerable population. This Special Issue aims to critically evaluate the current evidence regarding vaccine efficacy and safety in patients with immune-mediated intestinal diseases. It will explore the immune mechanisms underlying vaccine response alterations, the impact of immunosuppressive therapies on vaccine effectiveness, and the potential risks associated with vaccination in this population. Additionally, this Special Issue may discuss the available guidelines and recommendations for vaccination in this population, highlighting areas of uncertainty and areas that require further research. We encourage the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles related.

---

### Guest Editors

Dr. Adi Lahat

Department of Gastroenterology, Chaim Sheba Medical Center,  
Affiliated to Tel Aviv University, Tel Aviv, Israel

Dr. Kassem Sharif

Department of Gastroenterology, Chaim Sheba Medical Center,  
Affiliated to Tel Aviv University, Tel Aviv, Israel

---

### Deadline for manuscript submissions

closed (30 November 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/177812](https://mdpi.com/si/177812)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).